Norwegian Ministry of Foreign Affairs

Det globale samarbeidet for å håndtere Covid-19-pandemien

John-Arne Røttingen, Ambassadør for global helse

Vaksine- og smitteverndagene 2021

Folkehelseinstituttet, 29.9.21

Global Situation

230,418,451
confirmed cases



4,724,876
deaths



Source: World Health Organization
Data may be incomplete for the current day or week.

Situation by WHO Region



Source: World Health Organization
Data may be incomplete for the current day or week.

Covid-19 tilfeller og dødsfall – ulike regioner





The COVID-19 epidemic curve





Courtesy of Gunnstein Norheim, based on Anderson et al 2020 Lancet, Kissler Lipsitch 2020

Norwegian Ministry of Foreign Affairs

© The Economist

Need for public private partnerships (PPPs)



Guinea Ebola ring vaccination trial 2014-16





Henao-Restrepo et al. Lancet July 31st 2015

Norwegian Ministry of Foreign Affairs

Research as part of epidemic preparedness

A systematic approach to accelerate product R&D to contribute to uncover research gaps

DISEASE	Generic/ methodol.	CCHF	Ebola & Marburg	Lassa fever	MERS-Cov & SARS	Nipah & henipavirviruses	Rift valley fever	Zika virus	Pathogen X	Plague	Chikungunya
R&D roadmap	✓	✓	✓	✓	✓	✓	✓	✓	✓		✓
TPP Vx	✓		✓	✓	✓	✓	✓	✓		✓	
TPP Tx	✓										
TPP Dx	✓	✓	✓	✓		✓		✓			
Regulatory standards		✓	✓	✓		✓		✓			
Vx trials design	✓	✓	✓	✓	✓	✓	✓	✓	generic	✓	✓
Tx trials design	✓	✓	✓	✓	✓	✓	✓			✓	✓
Decision tree design	✓					✓					✓
Trial simulator	✓					✓					✓
Innovative analysis	✓	Accumulating evidence from randomized clinical trials across outbreaks									✓

Testing of Ebola vaccines during the West African epidemic



Norwegian Ministry of Foreign Affairs

NORWEGIAN GOVERNMENT

The Federal Government

JAPANGOV
THE GOVERNMENT OF JAPAN

DEPARTMENT OF BIOTECHNOLOGY
Ministry of Science & Technology

BILL & MELINDA GATES foundation

wellcome

WORLD ECONOMIC FORUM

CEPI's priority pathogens

MERS	Lassa	Nipah	Chikungunya	Rift Valley fever	Disease X
5 vaccine candidates	6 vaccine candidates	4 vaccine candidates	2 vaccine candidates	2 vaccine candidates	3 platform technologies + COVID-19

- Enabling sciences incl. epidemiology studies
- Ebola

Mer enn 300 vaksiner under utvikling

Summary Information on Vaccine Products in Clinical Development

1. - Number of vaccines in clinical development	121
2. - Number of vaccines in pre-clinical development	194



3. - Candidates in clinical phase

Filter	All

Select phase of development (default is all)

Platform		Candidate vaccines (no. and %)	
PS	Protein subunit	43	36 %
VVnr	Viral Vector (non-replicating)	18	15 %
DNA	DNA	11	9 %
IV	Inactivated Virus	16	13 %
RNA	RNA	21	17 %
VVr	Viral Vector (replicating)	2	2 %
VLP	Virus Like Particle	5	4 %
VVr + APC	VVr + Antigen Presenting Cell	2	2 %
LAV	Live Attenuated Virus	2	2 %
VVnr + APC	VVnr + Antigen Presenting Cell	1	1 %
		121	



Mer enn 120 COVID-19 vaksiner under klinisk utprøving



COVID-19 vaccine doses administered by country income group

For vaccines that require multiple doses, each individual dose is counted. As the same person may receive more than one dose, the number of doses can be higher than the number of people in the population.



Source: Official data collated by Our World in Data, World Bank

OurWorldInData.org/covid-vaccinations • CC BY

Vaksinedekning





Share of the population fully vaccinated against COVID-19

Total number of people who received all doses prescribed by the vaccination protocol, divided by the total population of the country.

Our World in Data



Source: Official data collated by Our World in Data – Last updated 22 September 2021, 08:40 (London time)
Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.
OurWorldInData.org/coronavirus • CC BY

Høy vaksinasjons-dekning reduserer dødsfall



Coronavirus chart: see how your country compares | Free to read | Financial Times (ft.com)



Distribution of vaccination and hospitalization rates

Most hospital regions with high vaccination rates have lower hospitalization rates — and places with lower vaccination rates tend to see higher rates of admitted patients.



NORGE TELLER NED TIL GJENÅPNING

DIREKTE

Nå er Norge gjenåpnet!

Norge er gjenåpnet!

Konfetti

SE NÅ: Norge åpner opp!

Norwegian Ministry of Foreign Affairs

24 Sep

Covid-19: 2 783 new cases identified in SA, and 155 deaths

news24 Cebelihle Mthethwa

SHARE

Listen to this article 0:00

SUBSCRIBERS CAN LISTEN TO THIS ARTICLE

A patient gets a Covid-19 vaccine.

Getty Images

HEALTH • COVID-19

South Africa could become COVID 'mutation factory' because of large HIV-infected population, scientists say

BY **RENE VOLLGRAAFF**, **ANTONY SGUAZZIN**, **AMOGELANG MBATHA**, AND **BLOOMBERG**

September 15, 2021 2:10 PM GMT+2

World

Africa COVID-19 jab shortfall could take world 'back to square one': WHO



xford-AstraZeneca COVID-19 vaccine at the , Democratic Republic of the Congo, on May Mpiana)

17 Sep 2021 11:09AM
(Updated: 17 Sep 2021 11:09AM)

he Congo: Africa faces a shortfall of 470 oses this year after the COVAX alliance

Related Topics

Norwegian Ministry of Foreign Affairs

Norge, Sør Afrika og Malawi





Norge, Sør Afrika og Malawi





Global collaboration –
The Access to COVID-19 Tools (ACT) Accelerator

- **accelerate development** of tests, treatments & vaccines
- ensure **equitable access** to COVID-19 tools globally



Working with Governments, Civil Society and Industry for impact

ACTaccelerator
ACCESS TO COVID-19 TOOLS
Hosted by World Health Organization

Contributions | ACT-A's generous contributors have funded US$ 18.1 Bn so far, but still has a US$ 16.6 Bn gap for 2021

US$ 18.1 billion contributions for ACT-A received (as of 3 September 2021)



US$ 16.6 billion funding gap for 2021 (as of 3 September 2021)



Norwegian Ministry of Foreign Affairs

Note: all financial commitments can be accessed at https://www.who.int/publications/m/item/access-to-covid-19-tools-tracker.
1. US$ 18.1 billion include $470m contributed by the Diagnostics Consortium to procure automated and manual molecular tests for LMICs, and exclude pledges to Gavi for vaccine delivery as Gavi vaccine delivery costs are not reflected in the Strategy & Budget for 2021 2. Contributions <US$ 12m, and including $470m contributed by the Diagnostics Consortium to procure automated and manual molecular tests for LMICs 3. Including $2.7b of the new USG commitment of US$ 3.5 billion to the Global Fund – The precise composition of grants under C19RM 2021 will be determined by recipient countries and reported once funding requests are approved 4. COVAX AMC being fully funded for 2021, additional contributions to COVAX AMC do not reduce ACT-A funding gap for 2021.

ACTaccelerator
ACCESS TO COVID-19 TOOLS
Hosted by World Health Organization

Key achievements | within 18 months, ACT-Accelerator fundamentally improved our ability to tackle COVID-19 globally

Vaccines: can prevent COVID-19 everywhere

COVAX Facility:

- **has delivered ~ 250 m doses to 139 countries**
- **has signed supply agreements for >3.5 billion more doses**

Tests: can now quickly detect COVID anywhere

ACT-A Diagnostics:

- **has procured > 70 m tests for LICs and LMICs**
- **prepared to deliver >900 million tests in 2021-22**

Treatments: can save lives anywhere with O_2 & steroids

ACT-A Therapeutics:

- **prepared to deliver >100 million treatment courses in 2021-22**
- **launched the Emergency O_2 Task Force mobilizing >US$ 400 million to procure & deliver Oxygen**

Equitable Access: for uptake & use everywhere

Health systems support to deliver new products & PPE

Global Access & Allocation mechanisms

Norwegian Ministry of Foreign Affairs

UPDATED ON 8 SEPT 2021

COVAX Facility Supply Forecast

Ranged forecasts under low, most likely, and high scenarios

PRELIMINARY AND SUBJECT TO ASSUMPTIONS

COVAX Forecasted Supply, Cumulative, M doses, 2021 and 2022[1]



THREE BIGGEST DRIVERS OF UNCERTAINTY FOR COVAX SUPPLY

- **Timing and extent to which export controls in India are eased.** Easing of restrictions in Q4 could enable the release of hundreds of millions of doses to COVAX across both SII-AstraZeneca and SII-Novavax (latter pending regulatory approval)
- **Manufacturers prioritizing supply from global manufacturing networks to COVAX,** allowing COVAX to access doses that it has already secured and paid for under its existing APAs.
- **Timely regulatory approval** of candidates that COVAX has signed deals with including those being developed by Novavax, SII-Novavax, and Clover.

Norwegian Ministry of Foreign Affairs

Fra COVAX Supply Update, sept 2021

UPDATED ON 8 SEPT 2021

COVAX Facility Supply

Product-specific portfolio overview

PRELIMINARY AND SUBJECT TO ASSUMPTIONS

COVAX Available Supply, M doses, 2021 and 2022



1 "Committed doses" are doses that the COVAX Facility is required to procure. "Optional doses" are doses that the COVAX Facility has the option to procure in the future, but is not required to purchase. Once optional doses are exercised, they become committed doses.

2 "Dose donations" estimated based upon donor commitments to share new doses bilaterally with COVAX. The transfer of COVAX allocations from SFPs to AMC Participants are already included in the volumes secured by COVAX from legally-binding agreements.

3 US support has allowed COVAX to secure an additional 500M Pfizer/BioNTech doses. Reflecting US funding above its original pledge, 200M of these are recorded as a donation.

There are currently eleven vaccines in the COVAX portfolio:

1. SII: Covovax ("NVX-CoV2373")
2. SII: Covishield ("AZD1222")
3. Pfizer/BioNTech: BNT162b2
4. Moderna: mRNA 1273
5. Clover Biopharmaceuticals: SCB-2019 (CpG1018/Alum)
6. Sinovac: CoronaVac
7. Novavax : NVX-CoV2373
8. Janssen J&J[4]: Ad26COV2.S
9. AstraZeneca: ChAdOx1-S [recombinant] ("AZD1222")
10. Sinopharm: BBIBP-CorV
11. Sanofi-GSK: Recombinant Protein

PRINCIPLES FOR SHARING COVID-19 VACCINE DOSES WITH COVAX

GLOBAL CITIZEN ISSUES TAKE ACTION REWARDS PARTNERS STORE

NEWS DEFEAT POVERTY

Norway Commits to Donating COVID-19 Vaccines to Low-Income

Tweets Tweets & replies Media Likes

SMK Retweeted

Global Citizen Impact @GlblCtznImpact · May 8

Thank you @erna_solberg and Norway for your ongoing contribution to #COVAX! Your pledge to share 4.5M COVID-19 doses, in addition to the 700K already donated will help vulnerable communities from low-income countries stay protected from the pandemic! #VaxLive



3 52 138

Dr. Tom Frieden @DrTomFrieden · Mar 27

Vaccine nationalism is ethically inexcusable but politically inevitable. Must increase production. Tho vectored vaccines less expensive, easier to store& single-dose, mRNA technology has lower risk of missing production targets, more adaptable to variants and faster to scale. 13/

9 125 573

Dr. Tom Frieden @DrTomFrieden

Replying to @DrTomFrieden

Inevitable unless, of course, you're Norway. Again showing moral and financial global leadership. Norway played a critical role in development of many global health initiatives, and may well help create a better global system of solidarity and safety. bit.ly/3d7cbXy 14/

COVID-19 vaccine doses donated to COVAX

Shown is the number of vaccine doses donated to the COVAX initiative by each country. Donations are broken down by whether they have been announced, donated, or delivered.



Source: COVAX, ACT-Accelerator Hub. Data as of September 16, 2021.
OurWorldInData.org/coronavirus • CC BY
Note: COVAX is a worldwide initiative aimed at equitable access to COVID-19 vaccines. It is directed by Gavi, CEPI, and the WHO.

NEWS WEBSITE OF THE YEAR
The Telegraph

Subscribe now | Log in

Coronavirus | News | Politics | Sport | Business | Money | Opinion | Tech | Life | Style | Trav

See all News

COMMENT

Global collaboration is the world's best shot at ending t pandemic – here's what Big Pharma can do

Manufacturing and distribution problems are already causing supply const are four pragmatic ways pharmaceutical firms can help

DAG-INGE ULSTEIN | JOHN-ARNE RØTTINGEN

10 February 2021 • 7:30pm

COVID-19 | Global Health | Vaccin

4 principles for COVID-19



Image: REUTERS/Lisi Niesner - RC2VNL994

09 Feb 2021

Dag-Inge Ulstein
Minister of International Development , Government of Norway

John-Arne Rottingen
Chief Executive, The Research Council of Norway (RCN)

Ambassador Katherine Tai ✓
@AmbassadorTai

These extraordinary times and circumstances of call for extraordinary measures.

The US supports the waiver of IP protections on COVID-19 vaccines to help end the pandemic and we'll actively participate in @WTO negotiations to make that happen.

Office of the United States Trade Representative

FOR IMMEDIATE RELEASE:
May 5, 2021

CONTACT: media@ustr.eop.gov

STATEMENT FROM AMBASSADOR KATHERINE TAI ON THE COVID-19 TRIPS WAIVER

WASHINGTON – United States Trade Representative Katherine Tai today released a statement announcing the Biden-Harris Administration's support for waiving intellectual property protections for COVID-19 vaccines.

"This is a global health crisis, and the extraordinary circumstances of the COVID-19 pandemic call for extraordinary measures. The Administration believes strongly in intellectual property protections, but in service of ending this pandemic, supports the waiver of those protections for COVID-19 vaccines. We will actively participate in text-based negotiations at the World Trade Organization (WTO) needed to make that happen. Those negotiations will take time given the consensus-based nature of the institution and the complexity of the issues involved.

"The Administration's aim is to get as many safe and effective vaccines to as many people as fast as possible. As our vaccine supply for the American people is secured, the Administration will continue to ramp up its efforts – working with the private sector and all possible partners – to expand vaccine manufacturing and distribution. It will also work to increase the raw materials needed to produce those vaccines."

###

devex

ripped up in WTO by

Trade & Policy | WTO

Please consider a **Devex Pro subscription to support our journalism.**

WORLD TRADE ORGANIZATION

About WTO | News and events | Trade topics | WTO membership | Documents, data and resources | WTO and you

wto news → 2021 news → news item

TRIPS

30 APRIL 2021

TRIPS Council to continue to discuss temporary IP waiver, revised proposal expected in May

t a meeting of the Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS) on 30 pril 2021, WTO members agreed to continue consideration of the proposal for a temporary waiver f certain TRIPS obligations in response to COVID-19 and tasked the chair to report to the General ouncil on this decision at its next meeting on 5-6 May. Co-sponsors of the proposal announced ey will submit a revised version of the text initially submitted in October 2020 in a bid to reconcile ositions.

Norwegian Ministry
of Foreign Affairs